SEC Filing Summary: PerkinElmer, Inc. (10-K)
Business Context and Reporting Period
Company: PerkinElmer, Inc. (Note: The input metadata lists "REVVITY, INC.", but the filing text identifies the registrant as PerkinElmer, Inc.)
Reporting Period: Fiscal year ended December 29, 2002.
Business Overview: A leading provider of scientific instruments, consumables, and services to pharmaceutical, biomedical, environmental, and industrial markets. Operations are organized into three strategic business units: Life and Analytical Sciences, Optoelectronics, and Fluid Sciences.
Recent Developments:
- Combined Life Sciences and Analytical Instruments into a single business unit in October 2002.
- Completed the sale of the Security and Detection Systems business to L-3 Communications for approximately $100 million (discontinued operation).
- Approved plans to shut down Telecommunications Component and sell Entertainment Lighting businesses (discontinued operations).
- Reclassified Fluid Sciences as a continuing operation after failing to complete a planned sale within the required timeframe.
Key Financial Metrics
| Metric (in millions) | 2002 | 2001 |
|---|---|---|
| Sales (Continuing Ops) | $1,505.0 | $1,525.3 |
| Operating Income (Continuing Ops) | $24.3 | $129.7 |
| Net Loss | $(151.9) | $34.5 |
| Operating Cash Flow (Continuing Ops) | $108.2 | $145.3 |
| Total Debt | $805.5 | $724.1 |
| Stockholders' Equity | $1,252.3 | $1,363.6 |
Note: The 2002 Net Loss includes a $117.8 million after-tax charge related to the adoption of SFAS No. 142 (Goodwill impairment) and losses from discontinued operations.
Material Changes vs. Prior Period
- Revenue: Sales from continuing operations decreased 1% to $1,505.0 million. The decline was driven by lost sales from divested businesses and weakness in pharmaceutical, semiconductor, and aerospace markets, partially offset by the full-year inclusion of the Packard BioScience acquisition and favorable foreign exchange rates.
- Profitability: Operating income from continuing operations plummeted 81% to $24.3 million. This was primarily due to a $26.0 million restructuring charge for combining business units, a $17.2 million inventory write-down in Optoelectronics, and lower sales volumes leading to unabsorbed manufacturing costs.
- Accounting Change: The company adopted SFAS No. 142, ceasing goodwill amortization but recording a one-time $117.8 million impairment charge for goodwill associated with the lighting reporting unit within Optoelectronics.
- Debt Refinancing: In December 2002, the company completed a major refinancing, issuing $300 million in 8 7/8% senior subordinated notes and establishing a $315 million term loan to extend maturities and retire zero-coupon debentures.
Guidance, Outlook, and Risks
Management Commentary & Outlook:
- Restructuring: The company targets annualized pre-tax cost savings of $30.0 million to $45.0 million from the Life and Analytical Sciences combination, with $12.0 million to $25.0 million expected in 2003.
- Capital Expenditures: Expected to be approximately $40 million in 2003, focused on new products and shifting production to lower-cost geographies.
- Debt Obligations: The company has $186.5 million in escrow to retire remaining zero-coupon debentures by August 2003.
- Legal Proceedings: Subject to a class action lawsuit regarding alleged misleading statements (filed July 2002) and a patent infringement suit by Enzo Biochem (filed October 2002). Management intends to contest vigorously but cannot estimate potential losses.
- Environmental: Accrued $7.1 million for environmental remediation; potential exposure is not expected to be materially different from recorded amounts.
- Market Cyclicality: Results are sensitive to cyclical downturns in pharmaceutical, semiconductor, and aerospace industries.
Investor Verification Checklist
- Goodwill Impairment: Verify the assumptions used in the $117.8 million goodwill impairment charge for the Optoelectronics lighting unit under SFAS No. 142.
- Restructuring Execution: Monitor the realization of the targeted $30-$45 million in annualized cost savings from the Life and Analytical Sciences merger.
- Debt Covenants: Confirm compliance with financial ratios (leverage and coverage) under the new senior credit facility and 8 7/8% notes.
- Discontinued Operations: Review the final working capital adjustments on the Security and Detection Systems sale and the status of the Entertainment Lighting divestiture.
- Legal Exposure: Track developments in the Enzo Biochem patent litigation and the shareholder class action lawsuit.